DE60216458D1 - Verfahren zum auslösen einer anhaltenden immunreaktion - Google Patents

Verfahren zum auslösen einer anhaltenden immunreaktion

Info

Publication number
DE60216458D1
DE60216458D1 DE60216458T DE60216458T DE60216458D1 DE 60216458 D1 DE60216458 D1 DE 60216458D1 DE 60216458 T DE60216458 T DE 60216458T DE 60216458 T DE60216458 T DE 60216458T DE 60216458 D1 DE60216458 D1 DE 60216458D1
Authority
DE
Germany
Prior art keywords
enkephalin
triggering
immune response
continuous immune
immunocompromised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216458T
Other languages
English (en)
Other versions
DE60216458T2 (de
Inventor
Nicholas P Plotnikoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE60216458D1 publication Critical patent/DE60216458D1/de
Application granted granted Critical
Publication of DE60216458T2 publication Critical patent/DE60216458T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE60216458T 2001-05-16 2002-05-16 Verfahren zum auslösen einer anhaltenden immunreaktion Expired - Lifetime DE60216458T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29123701P 2001-05-16 2001-05-16
US291237P 2001-05-16
PCT/US2002/018529 WO2002092018A2 (en) 2001-05-16 2002-05-16 Methods for inducing sustained immune response

Publications (2)

Publication Number Publication Date
DE60216458D1 true DE60216458D1 (de) 2007-01-11
DE60216458T2 DE60216458T2 (de) 2007-09-27

Family

ID=23119478

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216458T Expired - Lifetime DE60216458T2 (de) 2001-05-16 2002-05-16 Verfahren zum auslösen einer anhaltenden immunreaktion

Country Status (8)

Country Link
US (2) US8633150B2 (de)
EP (1) EP1401474B1 (de)
CN (2) CN1541103A (de)
AT (1) ATE346605T1 (de)
AU (1) AU2002316221A1 (de)
DE (1) DE60216458T2 (de)
RU (1) RU2313364C2 (de)
WO (1) WO2002092018A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1814277A (zh) * 2005-12-07 2006-08-09 黄建寅 蛋氨酸脑啡肽在制备减轻放疗或化疗毒副作用的药物中的应用
AU2008306192A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of leptin (22-56 ) as a therapeutic agent
JP2010539018A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
US20100204132A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
KR20100058550A (ko) * 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도
AU2008297566A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100075439A (ko) * 2007-09-11 2010-07-02 몬도바이오테크 래보래토리즈 아게 치료제로서의 감마 1 ｍｓｈ 단독 또는 펜타가스트린과의 배합물
KR20100056511A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 빅 가스트린 ⅰ
KR20100059859A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃ형 나트륨이뇨 펩티드 단독 또는 뉴로펩티드 ａｆ와의 배합물의 용도
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP4593639B2 (ja) 2008-03-04 2010-12-08 株式会社マルハニチロ食品 ペプチド含有摂食調節剤
BRPI0909625B1 (pt) * 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
WO2013042811A1 (ko) * 2011-09-22 2013-03-28 (주)바이오에프디엔씨 카페오일알파네오엔돌핀 펩타이드 유도체 및 이의 항가려움 및 항아토피 소재로의 활용
US9937146B2 (en) 2016-03-23 2018-04-10 Bioadatp, Llc Enkephalin-influencing composition and method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
KR100333016B1 (ko) * 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins

Also Published As

Publication number Publication date
CN101417120A (zh) 2009-04-29
CN1541103A (zh) 2004-10-27
DE60216458T2 (de) 2007-09-27
US20030148942A1 (en) 2003-08-07
EP1401474A4 (de) 2005-05-11
RU2003136161A (ru) 2005-03-10
RU2313364C2 (ru) 2007-12-27
US20140024588A1 (en) 2014-01-23
EP1401474B1 (de) 2006-11-29
US8633150B2 (en) 2014-01-21
ATE346605T1 (de) 2006-12-15
AU2002316221A1 (en) 2002-11-25
WO2002092018A2 (en) 2002-11-21
WO2002092018A3 (en) 2003-12-11
EP1401474A2 (de) 2004-03-31

Similar Documents

Publication Publication Date Title
DE60216458D1 (de) Verfahren zum auslösen einer anhaltenden immunreaktion
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
CY1119389T1 (el) Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
PT932388E (pt) Forma de dosagem e metodo para administracao de farmacos
AR047229A1 (es) Administracion de conjugados polimericos de peptidos y proteinas terapeuticos por medio de microproyecciones revestidas
EA200401525A1 (ru) Способы лечения гепатита (варианты )
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
ATE292453T1 (de) Antivirale arznei
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2007079195A3 (en) Gastric retentive gabapentin dosage forms and methods for using same
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
DE60028207D1 (de) Transdermales therapeutisches system zur verabreichung von calciumantagonisten
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
UA2972U (uk) Спосіб лікування початкових проявів розсіяного склерозу
RU2007120403A (ru) Способ локальной терапии аутоиммунного артрита
BRPI0705943A2 (pt) formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
ECSP003771A (es) Metodo para prevenir la diarrea
MXPA05008425A (es) Metodo de tratamiento con nelfinavir.
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
UA42194A (uk) Спосіб введення лікарських препаратів, зосереджених в еритроцитарних контейнерах

Legal Events

Date Code Title Description
8364 No opposition during term of opposition